Keywords
Right ventricle
Right heart failure
Abstract
Background: There is evidence supporting the efficacy of Sacubitril /Valsartan for improving left heart failure, but few studies have examined its effects on right ventricular (RV) dysfunction. The current study aimed to investigate the effects of Sacubitril /Valsartan on RV dysfunction in patients with right heart failure.
Methods: The current study was a randomized and parallel clinical trial study. Patients over 18 years with any degree of right heart failure regardless of Left ventricular ejection fraction (LVEF) were included. The included patients were assigned randomly to three study arms using simple random allocation, i.e. the intervention group (Sacubitril Valsartan recipients) and the control groups (Losartan and Captopril recipients). The SPSS software version 19 was used for data analysis.
Results: The changes in LVEF, RV FAC, RV diameter, DOE grade, and TAPSE in the Sacubitril/Valsartan group were significantly higher than the other two groups. The severity of RV dysfunction, as well as TR (Tricuspid Regurgitation) severity, decreased significantly three months after the intervention compared to the beginning of the intervention in all groups especially in the Sacubitril/Valsartan group (p: 0.006). The mortality rate in the Sacubitril/Valsartan, Losartan, and Captopril groups, were 2(6.7%), 2(11.2%), and 1(7.7%) respectively (p: 0.83). Also, 27.6, 62.5, and 7.7% of cases in the Sacubitril/Valsartan, Losartan, and Captopril reached to optimum dose (p: 0.006).
Conclusion: Considering the results, it seems that Sacubitril/Valsartan has a positive effect on improving RV dysfunction in patients with right heart disorders.
References
Bhattacharya S, Heidler P, Varshney S. Incorporating neglected non-communicable diseases into the national health program—A review. Frontiers in public health. 2023;10:1093170.
Maleki Jamasbi M, Azami H, Samari B, Yousofvand V, Shourcheh E. Epidemiological Survey of Mortality and Morbidity Caused by Cardiovascular Diseases in Patients Admitted to the Cardiac Care Units of Hamadan Educational-medical Hospitals, Hamadan, Iran, in 2017. Journal of health research in community. 2019;5(3):27-38.
Qu C, Liao S, Zhang J, Cao H, Zhang H, Zhang N, et al. Burden of cardiovascular disease among elderly: based on the Global Burden of Disease Study 2019. European Heart Journal-Quality of Care and Clinical Outcomes. 2024;10(2):143-53.
Mendis S, Puska P, Norrving Be, Organization WH. Global atlas on cardiovascular disease prevention and control: World Health Organization; 2011.
Abushanab D, Al‐Badriyeh D, Marquina C, Liew D, Al‐Zaidan M, Ghaith Al‐Kuwari M, et al. Societal health and economic burden of cardiovascular diseases in the population with type 2 diabetes in Qatar. A 10‐year forecasting model. Diabetes, Obesity and Metabolism. 2024;26(1):148-59.
Steen Carlsson K, Faurby M, Nilsson K, Wolden ML. Cardiovascular events, mortality, early retirement and costs in> 50 000 persons with chronic heart failure in Sweden. ESC Heart Failure. 2024;11(1):54-64.
Kodeboina M, Piayda K, Jenniskens I, Vyas P, Chen S, Pesigan RJ, et al. Challenges and Burdens in the Coronary Artery Disease Care Pathway for Patients Undergoing Percutaneous Coronary Intervention: A Contemporary Narrative Review. International Journal of Environmental Research and Public Health. 2023;20(9):5633.
Benza R, Biederman R, Murali S, Gupta H. Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension. Journal of the American College of Cardiology. 2008;52(21):1683-92.
Tei C, Dujardin KS, Hodge DO, Bailey KR, McGoon MD, Tajik AJ, et al. Doppler echocardiographic index for assessment of global right ventricular function. Journal of the American Society of Echocardiography. 1996;9(6):838-47.
Kaul S, Tei C, Hopkins JM, Shah PM. Assessment of right ventricular function using two-dimensional echocardiography. American heart journal. 1984;107(3):526-31.
Ventetuolo CE, Klinger JR. Management of acute right ventricular failure in the intensive care unit. Ann Am Thorac Soc. 2014;11(5):811-22.
Hubers SA, Brown NJ. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. Circulation. 2016;133(11):1115-24.
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine. 2014;371(11):993-1004.
Lewis EF, Claggett BL, McMurray JJ, Packer M, Lefkowitz MP, Rouleau JL, et al. Health-related quality of life outcomes in PARADIGM-HF. Circulation: Heart Failure. 2017;10(8):e003430.
Masarone D, Errigo V, Melillo E, Valente F, Gravino R, Verrengia M, et al. Effects of sacubitril/valsartan on the right ventricular arterial coupling in patients with heart failure with reduced ejection fraction. Journal of Clinical Medicine. 2020;9(10):3159.
Correale M, Mallardi A, Mazzeo P, Tricarico L, Diella C, Romano V, et al. Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry. IJC Heart & Vasculature. 2020;27:100486.
Moliner-Abós C, Rivas-Lasarte M, Pamies Besora J, Fluvià-Brugues P, Solé-González E, Mirabet S, et al. Sacubitril/valsartan in real-life practice: experience in patients with advanced heart failure and systematic review. Cardiovascular drugs and therapy. 2019;33:307-14.
Lluri G, Lin J, Reardon L, Miner P, Whalen K, Aboulhosn J. Early experience with sacubitril/valsartan in adult patients with congenital heart disease. World Journal for Pediatric and Congenital Heart Surgery. 2019;10(3):292-5.
Appadurai V, Thoreau J, Malpas T, Nicolae M. Sacubitril/valsartan in adult congenital heart disease patients with chronic heart failure− a single centre case series and call for an international registry. Heart, Lung and Circulation. 2020;29(1):137-41.
Maurer SJ, Salvador CP, Schiele S, Hager A, Ewert P, Tutarel O. Sacubitril/valsartan for heart failure in adults with complex congenital heart disease. International Journal of Cardiology. 2020;300:137-40.
Zhang J, Du L, Qin X, Guo X. Effect of Sacubitril/Valsartan on the Right Ventricular Function and Pulmonary Hypertension in Patients With Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta‐Analysis of Observational Studies. Journal of the American Heart Association. 2022;11(9):e024449.
Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D. Effects of the angiotensin‐receptor neprilysin inhibitor on cardiac reverse remodeling: meta‐analysis. Journal of the American Heart Association. 2019;8(13):e012272.
Lyon RC, Zanella F, Omens JH, Sheikh F. Mechanotransduction in cardiac hypertrophy and failure. Circulation research. 2015;116(8):1462-76.
Aloia E, Cameli M, D'Ascenzi F, Sciaccaluga C, Mondillo S. TAPSE: an old but useful tool in different diseases. International journal of cardiology. 2016;225:177-83.
Damy T, Kallvikbacka-Bennett A, Goode K, Khaleva O, Lewinter C, Hobkirk J, et al. Prevalence of, associations with, and prognostic value of tricuspid annular plane systolic excursion (TAPSE) among out-patients referred for the evaluation of heart failure. Journal of cardiac failure. 2012;18(3):216-25.
Kjaergaard J, Akkan D, Iversen KK, Køber L, Torp‐Pedersen C, Hassager C. Right ventricular dysfunction as an independent predictor of short‐and long‐term mortality in patients with heart failure. European journal of heart failure. 2007;9(6-7):610-6.
Dini FL, Carluccio E, Simioniuc A, Biagioli P, Reboldi G, Galeotti GG, et al. Right ventricular recovery during follow‐up is associated with improved survival in patients with chronic heart failure with reduced ejection fraction. European Journal of Heart Failure. 2016;18(12):1462-71.
Yang Y, Shen C, Lu J, Fu G, Xiong C. Sacubitril/valsartan in the treatment of right ventricular dysfunction in patients with heart failure with reduced ejection fraction: a real-world study. Journal of Cardiovascular Pharmacology. 2022;79(2):177.
Nederend M, Kiès P, Regeer MV, Vliegen HW, Mertens BJ, Robbers-Visser D, et al. Tolerability and beneficial effects of sacubitril/valsartan on systemic right ventricular failure. Heart. 2023.
Nugara C, Giallauria F, Vitale G, Sarullo S, Gentile G, Clemenza F, et al. Effects of Sacubitril/Valsartan on Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction and the Role of Percentage of Delayed Enhancement Measured by Cardiac Magnetic Resonance in Predicting Therapeutic Response: A Multicentre Study. Cardiac Failure Review. 2023;9.